HER2-Positive Stomach Cancer: What ASCO Now Recommends
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
HER2-Positive Stomach Cancer: What ASCO Now Recommends
-
ナレーター：
-
著者：
Welcome to Onco Life Centre Podcast.
This episode looks at ASCO's August 2026 guideline update for HER2-positive gastric cancer, including what changed for first-line treatment and why biomarker testing now happens earlier.
You'll learn:
- Why ASCO updated its HER2-positive gastric cancer guideline in August 2026
- What the four newly recommended biomarker tests are
- How new trial results changed first-line treatment options
- What second-line options exist if first-line treatment stops working
- Why the timing of biomarker testing matters for patients
- Roughly what percentage of stomach cancers are HER2-positive
- What question patients should ask their care team about biomarker testing
- How often ASCO reviews this guideline going forward
This update reflects one of the more significant shifts in gastric cancer care in recent years, and it gives both patients and care teams a clearer path forward.
Blog Link: HER2-Positive Stomach Cancer: What ASCO Now Recommends
Send us Fan Mail
Thank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education.
Author: Dr. CHRISTINA NG VAN TZE
📍 Visit us at oncolifecentre.com
📞 Call: +60 3 2242 3260
📧 Book a consultation or ask a question — we're here to support your journey.